Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and a paucity of therapeutic options. Nintedanib (previously known as BIBF 1120) is a tyrosine kinase receptor antagonist which inhibits a number of key receptors, including those for platelet...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodcock, Hannah V, Molyneaux, Philip L, Maher, Toby M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693725/
https://www.ncbi.nlm.nih.gov/pubmed/23818761
http://dx.doi.org/10.2147/DDDT.S38833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693725/
https://www.ncbi.nlm.nih.gov/pubmed/23818761
http://dx.doi.org/10.2147/DDDT.S38833

Ejemplares similares